Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

Lucas M. Kimmig, David Wu, Matthew Gold, Natasha N Pettit, David Pitrak, Jeffery Mueller, Aliya N. Husain, Ece A. Mutlu, View ORCID ProfileGökhan M. Mutlu
doi: https://doi.org/10.1101/2020.05.15.20103531
Lucas M. Kimmig
1Department of Medicine, University of Chicago, Chicago, Illinois
2Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Wu
1Department of Medicine, University of Chicago, Chicago, Illinois
2Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Gold
1Department of Medicine, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha N Pettit
1Department of Medicine, University of Chicago, Chicago, Illinois
3Section of Infectious Diseases, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Pitrak
1Department of Medicine, University of Chicago, Chicago, Illinois
3Section of Infectious Diseases, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffery Mueller
4Department of Pathology, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aliya N. Husain
4Department of Pathology, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ece A. Mutlu
5Section of Gastroenterology and Hepatology, Rush University, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gökhan M. Mutlu
1Department of Medicine, University of Chicago, Chicago, Illinois
2Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gökhan M. Mutlu
  • For correspondence: gmutlu@uchicago.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and predispose to secondary infections.

Methods We retrospectively reviewed the medical record of critically ill COVID-19 patients during an 8-week span and compared the prevalence of secondary infection and outcomes in patients who did and did not receive tocilizumab. Additionally, we included representative histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at our institution.

Results 111 patients were identified, of which 48 had received tocilizumab while 63 had not. Receiving tocilizumab was associated with a higher risk of secondary bacterial (50% vs. 28.6%, p=0.021 and fungal (8.3% vs. 0%, p=0.078) infections. Consistent with higher number of infections, patients who received tocilizumab had higher mortality (39.6 vs. 17.4%, p=0.016). Seven cases underwent autopsy. In 3 cases who received tocilizumab, there was evidence of pneumonia on pathology. Of the 4 cases that had not been given tocilizumab, 2 showed evidence of aspiration pneumonia and 2 exhibited diffuse alveolar damage.

Conclusions Experimental therapies are currently being applied to COVID-19 outside of clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm. We seek to raise physician awareness of these issues and highlight the need to better understand the immune response in COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Not applicable

Funding Statement

None.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of Chicago IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available upon responsible request by contacting the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 06, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections
Lucas M. Kimmig, David Wu, Matthew Gold, Natasha N Pettit, David Pitrak, Jeffery Mueller, Aliya N. Husain, Ece A. Mutlu, Gökhan M. Mutlu
medRxiv 2020.05.15.20103531; doi: https://doi.org/10.1101/2020.05.15.20103531
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections
Lucas M. Kimmig, David Wu, Matthew Gold, Natasha N Pettit, David Pitrak, Jeffery Mueller, Aliya N. Husain, Ece A. Mutlu, Gökhan M. Mutlu
medRxiv 2020.05.15.20103531; doi: https://doi.org/10.1101/2020.05.15.20103531

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (896)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8764)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1857)
  • Geriatric Medicine (177)
  • Health Economics (387)
  • Health Informatics (1284)
  • Health Policy (642)
  • Health Systems and Quality Improvement (490)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10543)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1748)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (459)
  • Oncology (962)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1841)
  • Public and Global Health (3975)
  • Radiology and Imaging (650)
  • Rehabilitation Medicine and Physical Therapy (341)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (79)